Crossmark

Lower circulating endocannabinoid levels in children with autism spectrum disorder

Crossref DOI link: https://doi.org/10.1186/s13229-019-0256-6

Published Online: 2019-01-30

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aran, Adi https://orcid.org/0000-0001-9460-4689
Eylon, Maya

Harel, Moria

Polianski, Lola

Nemirovski, Alina

Tepper, Sigal

Schnapp, Aviad

Cassuto, Hanoch

Wattad, Nadia

Tam, Joseph
Funding

Funding for this research was provided by:

National Institute for Psychobiology in Israel, Hebrew University of Jerusalem (203-17-18)

Israel Society for Neuroscience (617/14)

BOL pharma (n/a)
License Information

Text and Data Mining valid from 2019-01-30
More Information

Article History

Received: 14 September 2018

Accepted: 18 January 2019

First Online: 30 January 2019

Ethics approval and consent to participate

: All research procedures were approved by the Shaare Zedek Medical Center Review Board and Israeli Ministry of Health prior to participant enrollment. Participants’ parents provided written consent prior to initiation of any experimental procedures, and written assent was obtained from participants when appropriate.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.